Back to library
SARMPhase1

RAD-140 (Testolone)

rad-one-forty

Research profile · How we handle evidence

Category

SARM

Compound type

Phase / Status

Phase1

Phase 1 clinical trials for breast cancer treatment. Not FDA approved. Research chemical. One of the most potent SARMs available.

Standard Dose

5-20mg/day

Once daily

Half-life

15-20 hours

Plasma elimination

Route(s)

IN / SU / OR

Intramuscular, Subcutaneous or Oral

Research Stage

Status Unknown

Research phase not specified; exercise appropriate caution.

Overview

RAD-140 is considered one of the most potent SARMs available. It gives strong anabolic (muscle-building) effects with very low androgenic (masculinizing) side effects. It's being researched for breast cancer treatment and brain protection. Still experimental - not approved. Think of it as the 'heavy hitter' of SARMs - strong results but also strong suppression.

Plain-language summary

RAD-140 is considered one of the most potent SARMs available. It gives strong anabolic (muscle-building) effects with very low androgenic (masculinizing) side effects. It's being researched for breast cancer treatment and brain protection. Still experimental - not approved. Think of it as the 'heavy hitter' of SARMs - strong results but also strong suppression.

Administration Routes

  • Intramuscular
  • Subcutaneous
  • Oral

Also known as

RAD-140TestoloneRADthe dry SARM

Mechanisms

1

Selective androgen receptor modulator with high anabolic-to-androgenic ratio (90:1). Activates androgen receptors in muscle and bone selectively. Basically turns on muscle-building genes without turning on the 'masculine' side effects.

Detailed mechanism

Selective androgen receptor modulator with high anabolic-to-androgenic ratio (90:1). Activates androgen receptors in muscle and bone selectively. Selectively binds to androgen receptors in muscle and bone tissue while minimizing effects on other organs, promoting anabolic effects with reduced side effects compared to traditional steroids.

Safety

Side effects

  • Testosterone suppression (significant)
  • Increased aggression
  • Hair loss (at higher doses, DHT pathway)
  • Potential liver enzyme elevation
  • PCT required after cycle

Reported benefits

  • Very high anabolic-to-androgenic ratio (90:1)
  • Significant lean muscle mass gains
  • Superior strength and power output
  • Neuroprotective properties (being researched)
  • Potential for breast cancer treatment
  • Minimal water retention

Safety profile

Safety profile varies. Consult healthcare provider before use.

Clinical trials

Phase 1 clinical trials completed, establishing safety profile.

Structure

View 3D structure

Verified structure

RAD-140 (Testolone)

Exact 2D structure can be rendered from a PubChem-backed canonical SMILES string.

Verified via PubChemMatched by casNumber
Source: PubChemLookup: 1182367-47-0InChIKey XMBUPPIEVAFYHO-KPZWWZAWSA-N
Chemical Formula
C20H16ClN5O2
Molecular Weight
393.83 g/mol
CAS Number
1182367-47-0
InChIKey
XMBUPPIEVAFYHO-KPZWWZAWSA-N

Stack Context

Stacks with

MK-677CardarineLGD-4033BPC-157

Comparison context

RAD-140 is the strongest SARM for lean mass, stronger than Ostarine but more suppressive. Unlike LGD-4033, which adds mass with some water retention, RAD-140 produces a drier, harder look. Compared to traditional anabolic steroids like Anavar, RAD-140 is less hepatotoxic but still suppresses natural testosterone significantly.

References

  1. 1

    RAD140, a selective androgen receptor modulator, reduces aggressive prostate tumor growth (Cancer Research)

    2017

    View source
  2. 2

    Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats (Endocrinology)

    2014

    View source
  3. 3

    Phase 1 first-in-human study of RAD-140 in hormone receptor-positive metastatic breast cancer (ClinicalTrials.gov)

    2017

    View source

This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.

Research-driven insights.Evidence-based decisions.